System for Coating a Tubular Implantable Medical Device

ABSTRACT

A system for coating a tubular implantable medical device, such as a stent, can include a rotatable applicator and a rotatable support for the medical device. The axes of rotation of applicator and the support can be substantially non-parallel.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a divisional of application Ser. No. 10/680,905,filed Oct. 7, 2003, which is incorporated herein by reference.

FIELD OF THE INVENTION

This invention relates to a system for coating a tubular implantablemedical device, such as a stent.

BACKGROUND

Blood vessel occlusions are commonly treated by mechanically enhancingblood flow in the affected vessels, such as by employing a tubularimplantable medical device known as a stent. Stents act as scaffoldings,functioning to physically hold open and, if desired, to expand the wallof the passageway. Stents are capable of being compressed, so that theycan be inserted through small lumens via catheters, and then expanded toa larger diameter once they are at the desired location.

FIG. 1 illustrates a conventional stent 10 formed from a plurality ofstructural elements including struts 12 and connecting elements 14. Theplurality of struts 12 are radially expandable and interconnected byconnecting elements 14 that are disposed between adjacent struts 12,leaving lateral openings or gaps 16 between adjacent struts 12. Struts12 and connecting elements 14 define a tubular stent body having anouter, tissue-contacting surface and an inner surface.

Stents are used not only for mechanical intervention but also asvehicles for providing biological therapy. Biological therapy can beachieved by medicating the stents. Medicated stents provide for thelocal administration of a therapeutic substance at the diseased site.Local delivery of a therapeutic substance is a preferred method oftreatment because the substance is concentrated at a specific site andthus smaller total levels of medication can be administered incomparison to systemic dosages that can produce adverse or even toxicside effects for the patient.

One method of medicating a stent involves the use of a polymeric carriercoated onto the surface of the stent. A composition including a solvent,a polymer dissolved in the solvent, and a therapeutic substancedispersed in the blend is applied to the stent by immersing the stent inthe composition or by spraying the composition onto the stent. Thesolvent is allowed to evaporate, leaving on the stent surfaces a coatingof the polymer and the therapeutic substance impregnated in the polymer.

As noted above, one of the methods of applying a drug composition to astent involves spraying the composition onto the stent. The compositioncan be atomized to produce small droplets. Atomization is used becausethe droplet size can be made smaller than the size of the stent'sstructural elements, thus enabling a substantially conformal coating.However, there are potential shortcomings associated with a spraycoating process. For instance, many of the drugs and polymers that areapplied to stents are toxic when inhaled by humans. As the polymericdrug solutions are atomized, therefore, great care must be taken toavoid occupational exposure to the personnel conducting the process.Hoods, glove boxes, enclosures, and shrouds can be used to prevent toxicaerosol inhalation, but at a cost of decreased efficiency and increasedexpenditures on equipment. In light of these safety and manufacturingconcerns, a stent coating method that avoids atomization of the coatingcan be advantageous.

Another disadvantage of a spray coating process is that the transferefficiency can be comparatively low. Only droplets which fall onto thestent's structural elements are incorporated into the coating. If thespray pattern is larger than the stent, much of the spray can be wasted.Moreover, the stent's body can have a number of open spaces or gapsbetween the structural elements that allow the spray to pass through,and therefore be unused. The components of the coating compositions canbe very expensive. For instance, many of the drugs applied to stents aresmall molecule agents or biologically derived substances such aspeptides and gene therapy agents that are very costly. A stent coatingmethod which transfers the coating solution in a more direct manner tothe stent structure would therefore have a manufacturing cost advantage.

Yet another shortcoming of a spray coating process is that it can bedifficult to direct the coating composition to a selected stent surfacesuch as only onto the outer surface of the stent. The outer ortissue-contacting surface of the stent is the surface that is pressedagainst the vessel wall. Drug released from the outer surface of thestent is mostly diffused into the tissue, thereby maximizing the localdelivery of the drug. Drug present on the inner or lumen contactingsurface of the stent, on the other hand, can diffuse into the bloodstream where it is transported by the blood flow to an area away fromthe site of stent implantation. For particular drugs, it may beadvantageous to have a stent where the coating is only present on theouter surface of the stent. For example, certain drugs can produceadverse or even toxic side effects for the patient when they arereleased into the blood stream and carried into the vascular system. Byhaving a drug coating limited to the outer surface of the stent, one canminimize the amount of these types of drugs that are delivered outsideof the treatment area.

There are other reasons to produce a stent that only has the drugcoating on the outer surface of the stent. In manufacturing drug elutingstents, one of the goals of the manufacturing process is to minimize thecontribution of the coating to the stent dimensions (i.e., to minimizethe thickness of the coating). By minimizing the thickness, or profile,of the stent's structural members, one can achieve bettermaneuverability as the stent is delivered to the site of implantation.Furthermore, because foreign materials in the body can elicit a chronicforeign body response, it is desirable to minimize the amount of polymerapplied to the stent body. By applying the polymeric drug coating toonly the outer surface of the stent, the amount of polymer exposed tothe body of the patient can be reduced.

Spray or dip coating processes coat both the inner and outer surfaces ofthe stent. Masking techniques can be used to limit the coatingapplication to the inner or outer surface. For example, a mandrel can beinserted through the longitudinal bore of the stent to mask the innersurface such that the coating is deposited only on the outer surface. Itmay be, however, desirable to coat the inner surface of the stent with afirst type of drug, such as an angiogenic drug, and the outer surfacewith a second type of a drug such as one used for the treatment ofrestenosis. If the inner surface of the stent is first masked for thedeposition of a coating on the outer surface of the strut, masking thecoated outer surface of the stent to form a coating on the inner surfaceof the stent may cause damage to the coating on the outer surface.Accordingly, a shortcoming of the conventional coating techniques is theinability of manufacturers to coat the inner and outer surfaces of thestent with different pharmaceutical agents.

Another shortcoming of the above-described method of medicating a stentis the potential for coating defects. While some coating defects can beminimized by adjusting the coating parameters, other defects occur dueto the nature of the application process. For example, during a spraycoating process, a stent is commonly supported by a mandrel. Because thespray applicator sprays the entire surface of a stent as the compositionis applied, and because there is a high degree of surface contactbetween the stent and the mandrel, there can be stent regions in whichthe liquid composition can flow, wick, and collect. Upon the removal ofthe coated stent from the mandrel, the excess coating may stick to themandrel, thereby removing some of the coating from the stent in the formof peels as shown in FIG. 2, or leaving bare areas as shown in FIG. 3.Alternatively, as illustrated in FIG. 4, the excess coating may stick tothe stent, thereby leaving excess coating as clumps or pools on thestruts or webbing between the struts. These types of defects can causeadverse biological responses after the coated stent is implanted into abiological lumen. For instance, the tissue surrounding the biologicallumen adjacent to the ends of stent 10 can adversely react to thecoating defects (known as the “edge effect.”)

Accordingly, the present invention provides a system and method forcoating a tubular implantable medical device that addresses these needs.

SUMMARY OF THE INVENTION

In aspects of the present invention, a system for coating a tubularimplantable medical device with a coating composition comprises anapplicator substrate and a mandrel. The applicator substrate has asurface configured to receive a composition and to transfer thecomposition to a tubular implantable medical device. The mandrel isconfigured to support the tubular implantable medical device in closeproximity to or in contact with the applicator substrate. In furtheraspects, the system further includes an apparatus to rotate the mandrel.In other aspects, the device includes a hollow, longitudinal bore, andthe applicator substrate is further configured to fit into the hollow,longitudinal bore of the medical device.

In aspects of the present invention, a system for coating a tubularimplantable medical device with a coating composition comprises areservoir, an application roller, and a support element. The reservoirholds a coating composition. The application roller is configured toreceive the coating composition from the reservoir. The support elementis configured to support a tubular implantable medical device in closeproximity to or in contact with the application roller. In furtheraspects, the system further comprises a metering roller in communicationwith the application roller. In other aspects the surface of theapplication roller has grooves.

The features and advantages of the inventions will be more readilyunderstood from the following detailed description which should be readin conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 illustrates a conventional stent;

FIGS. 2-4 are scanning electron microscope images of stent coatings withcoating defects;

FIG. 5 illustrates a coating system for coating a stent in accordancewith one embodiment of the present invention;

FIGS. 6A-6D are top views of applicator substrates in accordance withvarious embodiments;

FIG. 7 illustrates a system for leveling a coating composition inaccordance with one embodiment of the present invention;

FIG. 8 is a perspective view of a support assembly for a stent to beused during a coating process;

FIGS. 9-13 illustrate coating systems for coating a stent in accordancewith various other embodiments of the present invention;

FIGS. 14A and 14B illustrate a coating system for coating an innersurface of a stent in accordance with an embodiment of the presentinvention; and

FIG. 15 is a scanning electron microscope image of a stent coating inaccordance with the Example.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS Tubular ImplantableMedical Device

Herein is disclosed a method and system for coating a tubularimplantable medical device, such as a stent. In the interests ofbrevity, a method and system for coating a tubular stent including apolymeric coating are described herein. However, one of ordinary skillin the art will understand that other tubular medical devices havingtherapeutic capabilities can be coated using the system and method ofthe present invention. For example, the medical device can be apolymeric covering device such as a sheath.

Examples of tubular implantable medical devices for the presentinvention include self-expandable stents, balloon-expandable stents,stent-grafts, sheaths and grafts (e.g., aortic grafts). The underlyingstructure of the device can be of virtually any design. The device canbe made of a metallic material or an alloy such as, but not limited to,cobalt chromium alloy, stainless steel (316L), high nitrogen stainlesssteel, e.g., BIODUR 108, cobalt chrome alloy L-605, “MP35N,” “MP20N,”ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridiumalloy, gold, magnesium, or combinations thereof “MP35N” and “MP20N” aretrade names for alloys of cobalt, nickel, chromium and molybdenumavailable from Standard Press Steel Co., Jenkintown, Pa. “MP35N”consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum.“MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10%molybdenum. The device can also be made partially or completely frombioabsorbable or biostable polymers.

System and Method for Coating a Tubular Implantable Medical Device

As disclosed herein, a coating system can be used to coat a tubularstent by transferring a portion of a coating composition from thesurface of an applicator onto a stent. The coating composition can beapplied directly to the surface of the stent, or to a previously appliedlayer of a coating material. In one embodiment, referring to FIG. 5, acoating system 20 for coating a tubular stent 22 is illustrated toinclude a composition feeder 24 and an applicator 26 having anapplicator substrate 28. Feeder 24 can be used to apply a coatingcomposition 30 onto applicator substrate 28. Coating composition 30 caninclude a solvent and a polymer dissolved in the solvent. Coatingcomposition 30 can also include an active agent.

Feeder 24 can be any suitable apparatus configured to deposit coatingcomposition 30 onto applicator substrate 28. Representative examples offeeder 24 include a spray apparatus, a twin screw gravimetric feeder ora belt resin feeder. To realize greater process efficiency, coatingcomposition 30 can be introduced into the process by means ofindividually metered, continuous mass flow streams through feeder 24.The flow rate of coating composition 30 from feeder 24 can be from about0.02 mg/second to about 20 mg/second, for example about 1 mg/second.

As coating composition 30 is applied to stent 22, coating composition 30should be in a substantially free-flowing or liquid form. The viscosityof coating composition 30 when applied onto stent 22 can be at themaximum of about 10 centipoises at ambient temperature and pressure toabout 1000 centipoises at ambient temperature and pressure. Theconsistency of the coating composition can affect how the composition isreceived by stent 22.

Applicator substrate 28 can be capable of moving in a linear directiontowards stent 22 as indicated by arrow 32 to deposit coating composition30 on stent 22. Applicator 26, for instance, can be integrated with aplurality of conveyer rollers 34 that move applicator substrate 28towards stent 22. In other words, to provide movement, applicatorsubstrate 28 can be incorporated into a conveyer belt system that is acomponent of applicator 26. Applicator substrate 28 can be moved atabout 1 mm/second to about 12 mm/second, for example about 6 mm/second.

Stent 22 can be supported by a mandrel during the coating process. Themandrel can be used to position stent 22 in close proximity to or incontact with applicator substrate 28. The mandrel is configured to allowstent 22 to be rotated about a central longitudinal axis of stent 22during the coating process. The mandrel can also be configured so thatstent 22 can be rolled towards feeder 24 (i.e., moved in a lineardirection as shown by arrow 36). As shown in FIG. 5, the rotationalmotion of stent 22 is depicted by arrow 38. Stent 22 can be rotated sothat at least some of a layer 40 of coating composition 30 istransferred to outer surface 42 of stent 22. Rotational speed of stent22 depends on the speed of applicator substrate 28, and can be, forexample, from about 1 rpm to about 250 rpm, more narrowly from about 10rpm to about 120 rpm. In one embodiment, the mandrel is connected to amotor that provides rotational motion to stent 22 during the coatingprocess. In this embodiment, the rotation of stent 22 can driveapplicator substrate 28.

Applicator substrate 28 has a surface capable of receiving a layer ofthe coating composition as deposited from feeder 24. In one embodiment,the surface of applicator substrate 28 includes grooves 44 to receivethe coating composition. The surface of applicator substrate 28 caninclude grooves 44 having any suitable pattern. Referring to FIGS.6A-6D, the surface of applicator substrate 28 can have vertical grooves44 (FIG. 6A), horizontal grooves 44 (FIG. 6B), grooves 44 with a zigzag(FIG. 6C) and/or a discontinuous (FIG. 6D) pattern.

In one embodiment, applicator substrate 28 is substantially flat, andwithout any curvatures along the length of applicator substrate 28wherein stent 22 is coated. By providing a substantially flat surfacefor applicator substrate 28, the thickness of coating 46 applied tostent 22 can be substantially uniform. Applicator substrate 28 can bemade of a material that is flexible so that applicator substrate 28 canbe a component of the conveyer belt system as illustrated in FIG. 5. Inone embodiment, applicator substrate 28 can be made of a material thatis “non-stick,” having a low friction coefficient. The material shouldbe resistant to solvents and heat, which may be directed onto applicatorsubstrate 28 during the coating process.

Representative examples of materials that can be used for applicatorsubstrate 28 include polyurethanes, polyetheretherketone,polytetrafluoroethylene (Teflon™), Delrin™, Rulon™ Pebax™, Kynar™,Solef™, fluorinated ethylene-propylene copolymer, poly(vinylidenefluoride-co-chlorotrifluoroethylene), poly(vinyl fluoride),poly(ethylene terephthalate) (MYLAR), polyesters, or any suitable nylon.

Coating system 20 can include a leveling bar 48 to produce asubstantially uniform thickness for layer 40. Leveling bar 48 can besupported by any suitable structure and positioned at a set distancefrom applicator substrate 28 to define an opening through which coatingcomposition 30 is passed. The size of the opening is generallycomparable with the thickness of layer 40 on the stent side of levelingbar 48. Representative examples of the thickness of layer 40 includeabout 2.5 microns to about 1000 microns. In one embodiment, thethickness is about 25 microns to about 100 microns.

Referring to FIG. 7, a leveling system 50 that includes an air gun 52can be used to level coating composition 30. Air gun 52 can be capableof producing and directing an air flow to composition 30 applied toapplicator substrate 28. The air flow can be of sufficient force toreduce the profile of the composition mass that has been applied toapplicator substrate 28, and therefore level the composition to providea substantially uniform thickness. Air gun 52 can have a nozzle 54 witha relatively narrow slit to help provide the sufficient force. Use ofair gun 52 can be especially appropriate if coating composition 30 doesnot contain a highly volatile solvent, and has a low viscosity. By wayof example, the air flow velocity from air gun 52 can be from about 10meters/second to about 400 meters/second, more narrowly about 20meters/second to about 200 meters/second.

The mandrel can have any design that is suitable to support stent 22during the coating process. Referring to FIG. 8, stent 22 can beintegrated with a mandrel 56 that includes a plug 58 positioned at adistal end of a stem 60. Plug 58 can be circular in cross-section makingcontact with the inner surface of the stent. Plug 58 can have an almostequivalent diameter to the inner diameter of stent 22 as positioned onmandrel 56 so as to allow a friction fit between plug 58 and stent 22.By way of example, the outer diameter of the plug 58 can be from about 1mm to about 8 mm. Plug 58 can also have other cross-sectional shapes.

Plug 58 can be made of materials that are rigid or semi-pliable. Thematerial can be a “non-stick” material having a low friction coefficientand should be resistant to solvents and heat, which may be directed ontoplug 58 during the coating process. Representative examples of materialsthat can be used for plug 58 include the same materials listed above forapplicator substrate 28 as well as rigid materials such as stainlesssteel, titanium alloys, cobalt-chromium alloys, ceramics, metalliccarbides, inorganic carbides, and nitrides.

In addition to a single plug 58, stent 22 can also be held by othersupport designs. For example, stent 22 can be supported by two plugs,one at each end of stent 22. The two plugs in this type of supportapparatus could be connected by an internal mandrel. Alternatively, thetwo plugs could be unconnected having their relative orientationmaintained by an external fixture. The two end plugs can be conical inshape, and therefore, contact stent 22 at contact points at the endstruts.

As coating composition 30 is applied using coating system 20, thetemperature of coating composition 30 can be controlled during thecoating process. In one embodiment, coating system 20 includes atemperature controller for heating or cooling coating composition 30.The temperature controller can be used to heat or cool coatingcomposition 30 in order to produce and maintain a coating consistencythat is suitable for coating composition 30. Additionally, thetemperature controller can be used to cool coating composition 30especially if a volatile solvent is one of the components of coatingcomposition 30. The temperature controller can include any suitableapparatus for heating or cooling the coating composition, and can be incommunication with any suitable component of coating system 20. In oneembodiment, applicator substrate 28 is in communication with thetemperature controller so that the temperature controller can modify thetemperature of coating composition 30 during the coating process, forexample as coating composition is deposited from feeder 24. In anotherembodiment, mandrel 56 is in communication with the temperaturecontroller so that the temperature controller can modify the temperatureof stent 22 during the coating process.

In another embodiment of the present invention, referring to FIG. 9, acoating system 61 including an application roller 62 can be used toapply a layer of composition to the outer surface of stent 22. Stent 22can be supported by a mandrel so that stent 22 is in close proximity toor in contact with application roller 62. Referring to FIG. 9,application roller 62 is partially submerged in a coating compositiondisposed in a reservoir 64. The viscosity of the coating composition inreservoir 64 can be at the maximum, about 10 centipoises to about 10,000centipoises at ambient temperature and pressure. As application roller62 rotates, the coating composition is transferred from applicationroller 62 to stent 22.

Application roller 62 can be capable of rotating as indicated by arrow66, while stent 22 can be rotated as indicated by arrow 68. Asapplication roller 62 is rotated, a layer of coating composition isdeposited onto the outer surface of application roller 62. In oneembodiment, application roller 62 can include grooves or pores 70 thatfacilitate the transfer of the composition from reservoir 64 to theouter surface of application roller 62. In another embodiment,application roller 62 is completely smooth or only slightly textured. Inyet another embodiment, application roller 62 is surfaced with bristles,fibers, brushes, or other absorbent materials, including sponge orsponge-like material.

In one embodiment, application roller 62 is cylindrical in shape.Application roller 62 can have an outer circumference with a radius ofcurvature about equal to the radius of curvature of the outercircumference of stent 22. Also, the outer diameter of applicationroller 62 can be larger than the outer diameter of stent 22. By way ofexample, the outer diameter of application roller 62 can be from about 3mm to about 50 mm for a stent having an outer diameter of about 1 mm toabout 8 mm. Since stent 22 is radially expandable, when referring to thediameter stent 22, the measurement is the diameter of stent 22 aspositioned on a fixture during the coating process.

Rotation of application roller 62 and stent 22 are arranged so that thetangential velocities at the stent and roller surfaces are similar. Therotational speeds can therefore differ according the difference betweenthe radius of application roller 62 and the radius of stent 22. Rotationof stent 22 can be from about 1 rpm to about 200 rpm, more narrowly fromabout 2 rpm to about 30 rpm. Since application roller 62 can have alarger diameter than stent 22, rotation of application roller 62 can befrom about 0.02 rpm to about 500 rpm, more narrowly from about 0.04 rpmto about 80 rpm.

Coating system 61 can also include a leveling blade 72 to produce asubstantially uniform thickness on the outer surface of applicationroller 62. Leveling blade 72 can be supported by any suitable structureand can be positioned at a set distance from application roller 62 toproduce a selected thickness for the composition applied to the surfaceof application roller 62. Coating system 61 can include a temperaturecontroller. Any suitable component of coating system 61 can be incommunication with the temperature controller, such as the mandrelsupporting stent 22, application roller 62 and/or reservoir 64. A motorcan be used to drive application roller 62 or stent 22.

In another embodiment, referring to FIG. 10, a coating system 74 canhave a metering roller 76 positioned in close proximity to anapplication roller 78. In one embodiment, application roller 78 and/ormetering roller 76 are cylindrical in shape. Application roller 78 canhave an outer surface configured to receive a composition from feeder24. Application roller 78 can be capable of rotating as illustrated byarrow 80. Metering roller 76, in turn, can be capable of rotating asshown by arrow 82. The rotational direction of metering roller 76 can beopposite from the direction of application roller 78 to provide acontrolled deposition of coating composition 30 onto the surface ofapplication roller 78. Coating system 74 can further include a barrier84 positioned in close proximity to the outer surface of metering roller76. Barrier 84 can be supported by any suitable structure and can beused to prevent excess composition from being carried away by meteringroller 76 as metering roller 76 is rotated.

Feeder 24 can be any suitable apparatus configured to deposit coatingcomposition 30 onto application roller 78. As an alternative or inaddition to feeder 24, application roller 78 can be configured to havean internal deposition system capable of depositing the coatingcomposition onto the outer surface of application roller 78. Forexample, application roller 78 can include an open pore network incommunication with a composition reservoir disposed in the interior ofapplication roller 78. A pressure applied to the reservoir withinapplication roller 78 can force the composition from the reservoir toouter surface 86.

Coating system 74 can include a temperature controller. Any suitablecomponent of coating system 74 can be in communication with thetemperature controller, such as the mandrel supporting stent 22, feeder24, application roller 78, and/or metering roller 76. As noted above,the temperature controller can be used to heat or cool coatingcomposition 30 as appropriate.

In another embodiment of the present invention, referring to FIG. 11, acoating system 88 can have an application roller 90 that is used toapply a coating composition along the length of stent 22. The coatingcomposition can be applied to the surface of application roller 90 bythe methods as described herein. The composition can also be applied bydipping application roller 90 into a coating composition prior to thecoating of stent 22. Application roller 90 can then be rolled along thelength of stent 22 to apply a stripe of coating composition. Stent 22can be mounted on a mandrel that is capable of maintaining a fixedposition for stent 22 as application roller 90 is applying thecomposition. Once application roller 90 has completed one pass along thelength of stent 22, stent 22 can be rotated, and then application roller90 can apply another stripe of coating composition to stent 22. Coatingsystem 88 can include a temperature controller. Any suitable componentof coating system 88 can be in communication with the temperaturecontroller, such as the mandrel supporting stent 22, or applicationroller 90.

In a further embodiment, referring to FIG. 12, a coating system 91including an application roller 92 and a support roller 94 can be usedto apply a layer of composition to the outer surface of stent 22.Application roller 92 is partially submerged in reservoir 64. Asapplication roller 92 and stent 22 are rotated, application roller 92receives coating composition 30 from reservoir 64, and transfers coatingcomposition 30 to stent 22. Coating system 91 can also have an optionalleveling bar positioned in close proximity to the surface of applicationroller 92. For example, the leveling bar can be located at a positionwhere the coated surface of application roller 92 emerges from reservoir64. In this embodiment, instead of being supported by a mandrel, stent22 can be supported by application roller 92 and support roller 94during the coating process. Additionally, support roller 94 can berotated to provide rotational motion to stent 22 during the coatingprocess. Coating system 91 can also include a temperature controller.

Referring to FIG. 13, in another embodiment, a coating system 96 can beused to coat stent 22. Coating system 96 includes reservoir 64 and asupport assembly 98 that is connected to a rotating apparatus. Supportassembly 98 includes a mandrel 100 and stems 102. For the coatingprocess using coating system 96, stent 22 is partially submerged intocoating composition 30 along the longitudinal length of stent 22. Stent22 is then rotated while in a substantially horizontal position to coatstent 30 with coating composition 30.

As illustrated by FIG. 13, by using support assembly 98, stent 22 can bepositioned so that only the outer surface of stent 22 is in contact withthe surface of coating composition 30 as disposed in reservoir 64. Thecoating process can include rotating stent 22 while the outer surface ofstent 22 barely touches coating composition 30. By precisely positioningstent 22, the outer surface of stent 22 can be coated without coatingthe inner surface of stent 22.

The method of using coating system 96 can include selecting processparameters that account for the viscosity and surface tension of coatingcomposition 30. Coating composition 30 that is applied using coatingsystem 96 has a viscosity range that is lower than the viscosity rangeof coating composition 30 as applied using the other embodimentsdescribed herein. The viscosity is lower so that coating composition 30can coat in a conformal manner onto stent 22 as stent 22 is rotated. Theviscosity for coating composition 30 for this embodiment can be about 2centipoises at ambient temperature and pressure to about 500 centipoisesat ambient temperature and pressure. The viscosity of coatingcomposition 30 in reservoir 64 can be adjusted by selecting solutes(e.g., polymers) having a lower molecular weight, increasing the ratioof solvent to solute of coating composition 30, selecting a solvent thatmore effectively dissolves the solute, and/or adjusting the temperaturevia a temperature controller in communication with reservoir 64. Forinstance, the temperature controller can heat coating composition 30 inreservoir 64 in order to decrease the viscosity of coating composition30. Additionally, the surface tension can be lowered by using additivesin coating composition 30 such as surfactants, selecting an appropriatesolvent and/or adjusting the temperature of reservoir 64. For instance,raising the temperature of coating composition 30 to near the solventboiling point will lower the surface tension, allowing the coating to bemore conformal and reduce the webbing produced by the process.

In another embodiment, a system is provided for coating an inner surfaceof stent 22. Coating just the inner surface can be advantageous for thedelivery of therapeutic agents to the blood system to prevent thrombosisor promote rapid reendothelialization. For instance, certain drugs mayeffectively treat cardiovascular injuries when carried away by the bloodflow to an area adjacent to the site of stent implantation. These drugs,for example, may be used to treat “edge restenosis.” Referring to FIGS.14A and 14B, a coating system 104 includes a stent 22 and an applicationroller 106. The outer surface of application roller 106 can be coatedwith a wet coating by dipping, or other coating methods as describedherein, before contacting the inner surface of stent 22. Applicationroller 106 can then be inserted into the longitudinal bore of stent 22and rolled around the inner circumference of stent 22. As with the abovedescribed embodiments, coating system 104 can include a temperaturecontroller for heating or cooling coating composition 30 during thecoating process.

Application roller 106 can have a smooth surface, or be coated with anabsorbent material to facilitate loading the outer surface of applicatorroller 106 with the coating composition. Application roller 106 can besupported by a stem 110. Stent 22, in turn, can be supported in a tube108. Tube 108 can have an inner diameter that is slightly larger thanthe outer diameter of stent 22 and masks an outer surface 112 of stent22. Application roller 106 can be sized to provide an effectivecircumference to deliver a coating composition to the inner surface ofstent 22. By way of example, the outer diameter of application roller106 can be from about 0.5 mm to about 5 mm for a stent having an innerdiameter of about 0.9 mm to about 9.9 mm. In one embodiment, applicationroller 106 and/or tube 108 are in communication with a temperaturecontroller.

Multiple repetitions for applying the coating composition can beperformed using the system and method of the present invention. Theamount of composition applied by each repetition can be about 1microgram/cm² (of stent surface) to about 100 micrograms/cm², forexample less than about 10 micrograms/cm² per application. Eachrepetition can be followed by removal of a significant amount of thesolvent(s). Depending on the volatility of the particular solventemployed, the solvent can evaporate essentially upon contact with thestent. Alternatively, removal of the solvent can be induced by bakingthe stent in an oven at a mild temperature (e.g., 60° C.) for a suitableduration of time (e.g., 2-4 hours) or by the application of warm air.The application of warm air between each repetition prevents coatingdefects and minimizes interaction between the active agent and thesolvent. The temperature of the warm air can be from about 30° C. toabout 60° C., more narrowly from about 40° C. to about 50° C. The flowrate of the warm air can be from about 20 cubic feet/minute (CFM) (0.57cubic meters/minute (CMM)) to about 80 CFM (2.27 CMM), more narrowlyabout 30 CFM (0.85 CMM) to about 40 CFM (1.13 CMM). The warm air can beapplied for about 3 seconds to about 60 seconds, more narrowly for about10 seconds to about 20 seconds. By way of example, warm air applicationscan be performed at a temperature of about 50° C., at a flow rate ofabout 40 CFM, and for about 10 seconds.

Any suitable number of repetitions of applying the composition followedby removing the solvent(s) can be performed to form a coating of adesired thickness or weight. The coating process as described herein canbe used to form a coating on the stent having a thickness of about 0.5microns to about 100 microns, more narrowly, about 1 micron to about 20microns.

Operations such as wiping, centrifugation, or other web clearing actscan also be performed to achieve a more uniform coating. Briefly, wipingrefers to the physical removal of excess coating from the surface of thestent; and centrifugation refers to rapid rotation of the stent about anaxis of rotation. The excess coating can also be vacuumed off of thesurface of the stent.

The stent can be at least partially preexpanded prior to the applicationof the composition. For example, the stent can be radially expandedabout 20% to about 60%, more narrowly about 27% to about 55%—themeasurement being taken from the stent's inner diameter at an expandedposition as compared to the inner diameter at the unexpanded position.The expansion of the stent, for increasing the interspace between thestent struts during the application of the composition, can furtherprevent “cob web” formation between the stent struts.

Coating Composition

As noted above, the coating composition can include a solvent and apolymer dissolved in the solvent, and optionally an active agent.Representative examples of polymers that can be used to coat a medicaldevice in accordance with the present invention include ethylene vinylalcohol copolymer (commonly known by the generic name EVOH or by thetrade name EVAL); poly(hydroxyvalerate); poly(L-lactic acid);polycaprolactone; poly(lactide-co-glycolide); poly(hydroxybutyrate);poly(hydroxybutyrate-co-valerate); polydioxanone; polyorthoester;polyanhydride; poly(glycolic acid); poly(D,L-lactic acid); poly(glycolicacid-co-trimethylene carbonate); polyphosphoester; polyphosphoesterurethane; poly(amino acids); cyanoacrylates; poly(trimethylenecarbonate); poly(iminocarbonate); copoly(ether-esters) (e.g. PEO/PLA);polyalkylene oxalates; polyphosphazenes; biomolecules, such as fibrin,fibrinogen, cellulose, starch, collagen and hyaluronic acid;polyurethanes; silicones; polyesters; polyolefins; polyisobutylene andethylene-alphaolefin copolymers; acrylic polymers and copolymers; vinylhalide polymers and copolymers, such as polyvinyl chloride; polyvinylethers, such as polyvinyl methyl ether; polyvinylidene halides, such aspolyvinylidene fluoride, polyvinylidene chloride poly(vinylidenefluoride-co-hexafluoropropene), and poly(vinylidenefluoride-co-chlorotrifluoroethylene); polyacrylonitrile; polyvinylketones; polyvinyl aromatics, such as polystyrene; polyvinyl esters,such as polyvinyl acetate; copolymers of vinyl monomers with each otherand olefins, such as ethylene-methyl methacrylate copolymers,acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetatecopolymers; polyamides, such as Nylon 66 and polycaprolactam; alkydresins; polycarbonates; polyoxymethylenes; polyimides; polyethers; epoxyresins; polyurethanes; rayon; rayon-triacetate; cellulose; celluloseacetate; cellulose butyrate; cellulose acetate butyrate; cellophane;cellulose nitrate; cellulose propionate; cellulose ethers; andcarboxymethyl cellulose.

“Solvent” is defined as a liquid substance or composition that iscompatible with the polymer and is capable of dissolving the polymer atthe concentration desired in the composition. Examples of solventsinclude, but are not limited to, dimethylsulfoxide, chloroform, acetone,water (buffered saline), xylene, methanol, ethanol, 1-propanol,tetrahydrofuran, 1-butanone, dimethylformamide, dimethylacetamide,cyclohexanone, ethyl acetate, methylethylketone, propylene glycolmonomethylether, isopropanol, isopropanol admixed with water, N-methylpyrrolidinone, toluene, and combinations thereof.

The active agent can be for inhibiting the activity of vascular smoothmuscle cells. More specifically, the active agent can be aimed atinhibiting abnormal or inappropriate migration and/or proliferation ofsmooth muscle cells for the inhibition of restenosis. The active agentcan also include any substance capable of exerting a therapeutic orprophylactic effect in the practice of the present invention. Forexample, the agent can be for enhancing wound healing in a vascular siteor improving the structural and elastic properties of the vascular site.

By using the system and method of the present invention, the same activeagent can be applied to the inner and outer surfaces of stent 22.Alternatively, different active agents can be applied to the twosurfaces. For example, the outer surface of stent 22 can be coated witha drug that is capable of treating restenosis. The inner surface ofstent 22, on the other hand, can be coated with an angiogenic drug.

Examples of agents include antiproliferative substances such asactinomycin D, or derivatives and analogs thereof (manufactured bySigma-Aldrich 1001 West Saint Paul Avenue, Milwaukee, Wis. 53233; orCOSMEGEN available from Merck). Synonyms of actinomycin D includedactinomycin, actinomycin IV, actinomycin I₁, actinomycin X₁, andactinomycin C₁. The active agent can also fall under the genus ofantineoplastic, anti-inflammatory, antiplatelet, anticoagulant,antifibrin, antithrombin, antimitotic, antibiotic, antiallergic andantioxidant substances. Examples of such antineoplastics and/orantimitotics include paclitaxel (e.g., TAXOL® by Bristol-Myers SquibbCo., Stamford, Conn.), docetaxel (e.g., Taxotere, from Aventis S. A.,Frankfurt, Germany), methotrexate, azathioprine, vincristine,vinblastine, fluorouracil, doxorubicin hydrochloride (e.g., Adriamycin®from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g., Mutamycin®from Bristol-Myers Squibb Co., Stamford, Conn.). Examples of suchantiplatelets, anticoagulants, antifibrin, and antithrombins includesodium heparin, low molecular weight heparins, heparinoids, hirudin,argatroban, forskolin, vapiprost, prostacyclin and prostacyclinanalogues, dextran, D-phe-pro-arg-chloromethylketone (syntheticantithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membranereceptor antagonist antibody, recombinant hirudin, and thrombininhibitors such as Angiomax a (Biogen, Inc., Cambridge, Mass.). Examplesof such cytostatic or antiproliferative agents include angiopeptin,angiotensin converting enzyme inhibitors such as captopril (e.g.,Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.),cilazapril or lisinopril (e.g., Prinivil® and Prinzide° from Merck &Co., Inc., Whitehouse Station, N.J.), calcium channel blockers (such asnifedipine), colchicine, fibroblast growth factor (FGF) antagonists,fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (aninhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand nameMevacor® from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonalantibodies (such as those specific for Platelet-Derived Growth Factor(PDGF) receptors), nitroprusside, phosphodiesterase inhibitors,prostaglandin inhibitors, suramin, serotonin blockers, steroids,thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), andnitric oxide. An example of an antiallergic agent is pemirolastpotassium. Other therapeutic substances or agents which may beappropriate include alpha-interferon, genetically engineered epithelialcells, dexamethasone and rapamycin and structural derivatives orfunctional analogs thereof, such as 40-O-(2-hydroxy)ethyl-rapamycin(known by the trade name of EVEROLIMUS available from Novartis),40-O-(3-hydroxy)propyl-rapamycin,40-0-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

EXAMPLE

Some embodiments of the present invention are illustrated by thefollowing Example. The Example is being given by way of illustrationonly and not by way of limitation. The parameters and data are not beconstrued to unduly limit the scope of the embodiments of the invention.

A 20% EVAL solution in N,N-dimethlyacetamide (DMAC) (w/w) was prepared.A bead of the solution was applied to the surface of a stainless steel(316L) coupon. The bead was formed into a thin film by dragging a glassslide, held lengthwise, down the length of the coupon. A 12 mm VISIONstent (Guidant Corporation) was expanded to 0.069 inches (1.75 mm)(inner diameter), mounted onto a section of a thin walled stainlesssteel tubing with an outer diameter of 0.07 inches (1.78 mm). The stentwas then carefully laid down at one end of the thin film of polymersolution. The stent was rolled along the wet polymer film to coat theentire circumference of the outer surface of the stent. The stent wasbaked at 80° C. for one hour. After baking, the stent was removed fromthe tube.

The stent was weighed and it was determined that the process applied apolymeric coating of 70 μg. The coating was then studied using aScanning Electron Microscope (SEM) to view the distribution of thecoating and to determine if there were visible coating defects as aresult of the coating process. As illustrated in FIG. 15, the coatingwas limited to the outer surface of the stent and there weresubstantially no visible coating defects.

While particular embodiments of the present invention have been shownand described, it will be obvious to those skilled in the art thatchanges and modifications can be made without departing from thisinvention in its broader aspects. Therefore, the appended claims are toencompass within their scope all such changes and modifications as fallwithin the true spirit and scope of this invention. It is not intendedthat the invention be limited, except by the appended claims.

1. A system for coating a tubular implantable medical device with acoating composition, the system comprising: an applicator substrateincluding a surface configured to receive a composition and to transferthe composition to a tubular implantable medical device; and a mandrelconfigured to support the tubular implantable medical device in closeproximity to or in contact with the applicator substrate.
 2. The systemof claim 1, wherein the applicator substrate is configured to rotateabout a first rotational axis, and the mandrel is configured to rotateabout a second rotational axis that is not parallel to the firstrotational axis.
 3. The system of claim 2, wherein the applicatorsubstrate is configured to move over the mandrel in a linear directionthat is substantially parallel to the second rotational axis.
 4. Thesystem of claim 1, wherein the applicator substrate is configured tomove over the mandrel in a linear direction, and the mandrel isconfigured to rotate about a rotational axis that is substantiallyparallel to the linear direction.
 5. The system of claim 1, furthercomprising an apparatus to rotate the mandrel.
 6. The system of claim 1,wherein the medical device comprises a hollow, longitudinal bore andwherein the applicator substrate is further configured to fit into thehollow, longitudinal bore of the medical device.
 7. The system of claim1, wherein an outer surface of the mandrel comprises a non-stickmaterial.
 8. The system of claim 1, further comprising a levelingapparatus configured to be positioned along the surface of theapplicator substrate for reducing variation of composition thickness. 9.A system for coating a tubular implantable medical device with a coatingcomposition, the system comprising: a reservoir holding a coatingcomposition; an application roller configured to receive the coatingcomposition from the reservoir; and a support element to support atubular implantable medical device in close proximity to or in contactwith the application roller.
 10. The system of claim 9, wherein theapplication roller is configured to rotate about a first rotationalaxis, and the support element is configured to rotate about a secondrotational axis that is not parallel to the first rotational axis. 11.The system of claim 10, wherein the application roller is configured tomove over the support element in a linear direction that issubstantially parallel to the second rotational axis.
 12. The system ofclaim 9, wherein the application roller is configured to move over thesupport element in a linear direction, and the support element isconfigured to rotate about a rotational axis that is substantiallyparallel to the linear direction.
 13. The system of claim 9, furthercomprising a metering roller in communication with the applicationroller.
 14. The system of claim 13, further comprising a barrierpositioned adjacent to the metering roller for removing excesscomposition from the metering roller.
 15. The system of claim 9, whereinan outer surface of the application roller has grooves.
 16. The systemof claim 9, wherein the reservoir is housed within the applicationroller, and the application roller comprises pores in an outer surfaceof the application roller and in communication with the reservoir suchthat the coating composition can flow from the reservoir and out of thepores to be disposed on the outer surface of the application roller. 17.The system of claim 9, further comprising a leveling member to provide auniform thickness of the coating composition on the surface of theapplication roller.
 18. The system of claim 9, further comprising atemperature controller in communication with the reservoir for heatingor cooling the coating composition.
 19. The system of claim 9, whereinthe support element is a cylindrical body configured to be inserted intoa longitudinal bore of the tubular implantable medical device.